19427992

Source:http://linkedlifedata.com/resource/pubmed/id/19427992

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0027686, umls-concept:C0234621, umls-concept:C0333348, umls-concept:C0443252, umls-concept:C0796392, umls-concept:C1274040, umls-concept:C1299003, umls-concept:C1517572, umls-concept:C1656863
pubmed:issue	2
pubmed:dateCreated	2009-7-21
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00645697
pubmed:abstractText	To assess the long-term role of bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) in inflammatory ocular neovascularization.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0370500
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1879-1891
pubmed:author	pubmed-author:AdanAlfredoA, pubmed-author:Al-SalemKhalilK, pubmed-author:ArevaloJ FernandoJF, pubmed-author:BankerAlay SAS, pubmed-author:BerrocalMariaM, pubmed-author:ChanWai-ManWM, pubmed-author:Chau TranThi HaTH, pubmed-author:DodwellDavidD, pubmed-author:FardeauChristineC, pubmed-author:GuthoffRainerR, pubmed-author:HrisomalosFrankF, pubmed-author:HrisomalosNicholasN, pubmed-author:LehoangPhucP, pubmed-author:MackensenFriederikeF, pubmed-author:MahendradasPadmamaliniP, pubmed-author:MansourAhmad MAM, pubmed-author:Mehio-SibaiAblaA, pubmed-author:NessThomasT, pubmed-author:TabbarahZuheirZ, pubmed-author:ZiemssenFockeF
pubmed:issnType	Electronic
pubmed:volume	148
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	310-316.e2
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19427992-Adult, pubmed-meshheading:19427992-Angiogenesis Inhibitors, pubmed-meshheading:19427992-Antibodies, Monoclonal, pubmed-meshheading:19427992-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19427992-Choroidal Neovascularization, pubmed-meshheading:19427992-Choroiditis, pubmed-meshheading:19427992-Female, pubmed-meshheading:19427992-Fluorescein Angiography, pubmed-meshheading:19427992-Follow-Up Studies, pubmed-meshheading:19427992-Humans, pubmed-meshheading:19427992-Injections, pubmed-meshheading:19427992-Male, pubmed-meshheading:19427992-Retrospective Studies, pubmed-meshheading:19427992-Tomography, Optical Coherence, pubmed-meshheading:19427992-Treatment Outcome, pubmed-meshheading:19427992-Uveitis, pubmed-meshheading:19427992-Vascular Endothelial Growth Factor A, pubmed-meshheading:19427992-Visual Acuity, pubmed-meshheading:19427992-Vitreous Body
pubmed:year	2009
pubmed:articleTitle	Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization.
pubmed:affiliation	Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; Rafic Hariri University Hospital, Beirut, Lebanon.
pubmed:publicationType	Journal Article, Multicenter Study